Next Steps For Bayer’s Essure Device Coming In February, FDA Says
This article was originally published in The Gray Sheet
Executive Summary
FDA will publicly announce actions it will take on Bayer’s Essure permanent birth control device at the end of February 2016 following its full review of the medical literature, adverse events reports, and input received during and after a September 24 advisory panel meeting on Essure, the agency said in a posting on its website.
You may also be interested in...
FDA Investigating Attorney, Physician Beefs With Bayer’s Essure PMA
FDA is investigating claims in a Citizen’s Petition by plaintiff’s attorneys that patients’ responses to the Essure permanent birth control device were tampered with in the pivotal trial, and two gynecologists' complaints of inflated marketing.
Essure Panel Stresses Need For Patient Follow-Up, But Stressed-Out Patients Say, ‘Recall It’
An FDA advisory panel recommended a collection of activities to mitigate risk in the use of Bayer Healthcare’s Essure permanent contraceptive device, but dozens of patients describing hypersensitivity, extreme pain, insert migration, irregular bleeding, ectopic pregnancy and perforation events urged FDA to recall the device.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.